Industry will pay 75% of the total cost of the government’s review of new drug and device submission, and half of the cost of authority-to-sell functions.

— From a Health Canada web site outlining a potential user fee proposal. “Health Canada poised to roll out user fees for med-tech products,” pp. 1, 9.